EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the successful completion of the planned discussion with the FDA leading to the confirmation to file a New Drug ...

GREENWICH, Conn., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oxford Lane Capital Corp. (NasdaqGS: OXLC) (NasdaqGS: OXLCP) (NasdaqGS: OXLCL) (NasdaqGS: OXLCO) (NasdaqGS: OXLCZ) (NasdaqGS: OXLCN) (NasdaqGS: OXLCI) (NasdaqGS: OXLCG) (the “Company,” “we,” or “our”) today announced the following net asset value (“NAV”) estimate as of November 30, 2025. Management’s unaudited estimate of the range of the NAV per share of our common stock as of November 30, 2025, is between $16.34 and $16.64. This estimate is not a compreh ...

公司战略与增长举措 - 公司战略性地为其机队增加了一架挑战者604型飞机 以强化其增长轨迹并扩大包机运力 [1] - 此次机队扩张反映了一项旨在加强市场地位并推动长期股东价值的严谨投资策略 [1] - 增加挑战者604是公司增长战略中的一个重要里程碑 旨在使公司能够利用商务和休闲航空市场持续的需求 [3] - 此次扩张体现了公司严谨的增长方法 对卓越运营的关注以及对为客户和利益相关者提供长期价值的承诺 [3] 运营与市场影响 - 新飞机将在未来几周内投入服务 旨在提升服务可用性 [1] - 此次收购旨在响应商务航空需求上升 扩大运营规模 [1] - 新飞机不仅增加了包机运力 还加强了公司满足商务和休闲航空市场不断增长需求的能力 [3] - 此次增加为公司提供了扩大在东海岸地区业务覆盖的灵活性 该地区正经历显著增长 [3] 公司背景与定位 - 公司是总部位于加利福尼亚州卡尔斯巴德的飞机包机提供商 服务于国际航空爱好者群体 [4] - 公司专注于在航空业内建立可信赖的合作伙伴关系 为客户提供定制化的航空解决方案 [4] - 公司注重可靠性、创新和可持续性 目标是持续超越期望 培养持久关系 并致力于成为全球私人航空旅行的首选 [4] - 公司继续执行其愿景 努力成为私人航空领域的领先提供商 [3]

Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced a strategic restructuring plan intended to position the Company for long-term value creation for patients and shareholders and improve its financial d ...

GTAO Becomes the First Publicly Quoted U.S. Investment Product Offering Exposure to TAO Token as the Network Prepares to Undergo Its First Halving EventSTAMFORD, Conn., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Grayscale, the world's largest digital asset-focused investment platform*, today announced Grayscale® Bittensor Trust (the “Trust”) has begun trading on OTCQX®, a premier secondary U.S. market operated by OTC Markets Group Inc, under the ticker GTAO. The firm also announced that GTAO is now SEC reporting. Bi ...

VANCOUVER, British Columbia, Dec. 11, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology business solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces it has signed an offer to acquire a surveying firm headquartered in the Mountain West/Rocky Mountain region of the US with existing licensing to operate in multiple states. The potential acquisition enhan ...

SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted how optical genome mapping (OGM) can enhance the detection of structural variants (SVs) with greater clarity and sensitivity than traditional cytogenetic and molecular techniques. Through platform presentations and poster sessions, multiple researchers emphasized the ...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Grayscale Bittensor Trust (TAO) (OTCQX: GTAO), one of the first investment vehicles that enables investors to gain exposure to the token underlying the Bittensor platform ("TAO"), has qualified to trade on the OTCQX® Best Market. Grayscale Bittensor Trust (TAO) begins trading today on OTCQX under the symbol “GTAO.” U.S. investor ...

核心观点 - Elicio Therapeutics公司宣布其候选疗法ELI-002 7P在正在进行的2期临床试验中诱导了显著的抗原扩散效应 在15名接受评估的患者中 有13名（87%）产生了针对非mKRAS新抗原的T细胞反应 这增强了其产生广泛、个性化抗肿瘤免疫的潜力 [1][3][5] 临床试验数据与结果 - 在AMPLIFY-7P 2期试验中 对90名可评估患者中的15名进行了抗原扩散分析 其中87%（13/15）的患者显示出针对非mKRAS肿瘤新抗原的特异性T细胞显著扩增 [3] - 在2期试验的该亚组中 针对非mKRAS抗原的T细胞反应中位数较基线增加了10.6倍 且90%的患者同时产生了CD4+和CD8+ T细胞反应 [4] - 在1期试验中 ELI-002 2P（n=25）和ELI-002 7P（n=12）的抗原扩散T细胞反应率分别为67%（6/9）和70%（7/10） 2期数据（87%）显示出提升趋势 [4] - ELI-002 7P在2期试验中（n=90）诱导mKRAS T细胞反应的比例高达99%（89/90） 在1期试验中（n=12）该比例为100%（7/7） [4] 技术机制与科学意义 - 抗原扩散指免疫反应从初始靶抗原扩展到新的次级肿瘤特异性抗原的过程 可能限制肿瘤逃避免疫反应的能力 从而产生更持久的疗效 [2] - ELI-002 7P诱导的广泛T细胞反应同时靶向mKRAS和其他个性化肿瘤抗原 这可能有助于产生更强大的抗肿瘤免疫 并具有预防复发的潜力 [3] - 公司认为 诱导广泛的抗肿瘤免疫可以通过扩大对多种肿瘤抗原的免疫识别来增强ELI-002 7P的疗效 支持更个性化和持久的临床反应 [4] 公司产品线与平台技术 - Elicio Therapeutics是一家临床阶段生物技术公司 致力于开发针对高发癌症的新型免疫疗法 主要针对mKRAS阳性的胰腺癌和结直肠癌 [6] - 公司的先导项目ELI-002是一种现货型免疫疗法候选药物 针对最常见的KRAS突变 这些突变驱动约25%的所有实体瘤 [6] - ELI-002 7P配方旨在针对七种最常见的KRAS突变提供免疫反应覆盖 这些突变存在于25%的实体瘤中 从而增加了潜在的患者群体 [8] - 公司的专有Amphiphile平台旨在将研究性免疫治疗剂直接递送至免疫系统的“大脑中枢”——淋巴结 以更有效地教育、激活和扩增关键免疫细胞 [9] - AMP平台通过附着在局部注射部位的蛋白质白蛋白上 随其进入淋巴组织 从而将免疫治疗剂直接递送至淋巴结 [10] 研发进展与未来计划 - ELI-002 7P目前正在mKRAS驱动的胰腺癌患者的1/2期试验中进行研究 [8] - 公司计划未来将ELI-002扩展到其他适应症 包括mKRAS阳性肺癌和其他mKRAS阳性癌症 [6] - 公司产品线还包括其他现货型癌症免疫疗法候选药物 如针对BRAF驱动癌症的ELI-007和针对p53热点突变的ELI-008 [6] - 更新的AMPLIFY-201 1期数据显示 在整个研究人群中 胰腺癌和结直肠癌患者的中位无复发生存期为16.3个月 中位总生存期为28.9个月 [6]

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular miniaturization and drive vellus-to-terminal hair regeneration by demonstrating that it prolongs anagen, stimulates keratin synthesis, and modulates the stem cell niche Full dataset will be presented during today’s ABS-201 Key Opinion Leader (KOL) seminar VANCOUVER, Wash. and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWI ...